Is ProPhase Labs, Inc. (PRPH) a Buy, Sell, or Hold?
OTC : PRPH
ProPhase Labs, Inc.
$0.05 USD
$0 (0.0%)
- Volume
- 40.5K
- Average Volume
- 89.22K
- Market Capitalization
- $700.81K
- P/E Ratio
- -0.01
- Dividend Yield
- 0.00%
- Price Target
- $140.00
- Year High
- $6.70
- Year Low
- $0.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.06
Company Overview
OTC
Ted William Karkus
Drug Manufacturers - Specialty & Generic
Healthcare
PRPH
19
US
USD
Liquidity Metrics
-15.05
0.06
0.05
0.00
0.00
Sales & Valuation
$4.34M
0.21
-1.04
-0.02
-2.51
Profitability
-$1.74
-$14.74M
-709.40%
-668.90%
-453.74%
-40.96%
P/E Metrics
-0.01
0.00
0.00
Analyst Price Target & Rating
$140.00
$140.00
$140.00
2/5
2 Analysts
-99.96%
Financial Health Scores
-3.86
2/9
-$52.5M
$58.75M
$59.34M
-$17.54M
Key Metrics (TTM)
$9.58M
2.82
-1.06
0.06
-453.74%
-146.49%
-3907.28%
-4402.75%
-6260 days
Company Executives
| Name | Title |
|---|---|
| Kevin Quinn | Chief Product Officer of Nebula Genomics |
| Ted William Karkus | Chairman & Chief Executive Officer |
| Jason Karkus | President of Nebula Genomics |
Poll Results
No votes yet today — be the first to share your view!
About ProPhase Labs, Inc. (OTC:PRPH) Stock
ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Products division, ProPhase Labs is actively involved in the entire process—from researching and developing to manufacturing, distributing, marketing, and selling—a range of over-the-counter (OTC) healthcare items and nutritional supplements within the United States. Notable offerings include dietary supplements like Legendz XL, which supports male sexual health, and Triple Edge XL, formulated to enhance energy and stamina. The Diagnostic Services segment provides crucial testing solutions, including PCR tests for SARS-CoV-2 (COVID-19) and its variant m ... utations, using both saliva and nasal swab collection methods. This segment also offers molecular testing for other respiratory pathogens and supplies personal genomics products and services. Additionally, ProPhase Labs extends its capabilities by providing comprehensive contract manufacturing services, covering product development, pre-commercialization activities, production, warehousing, and distribution. The company's diverse products and services reach consumers through a broad network of national chain drug stores, various regional retailers, and online platforms.
Frequently Asked Questions
-
What is the current ProPhase Labs, Inc. (PRPH) stock price?
-
ProPhase Labs, Inc.(OTC:PRPH) stock price is $0.05 in the last trading session. During the trading session, PRPH stock reached the peak price of $6.7 while $0.03 was the lowest point it dropped to. The percentage change in PRPH stock occurred in the recent session was 0.0% while the dollar amount for the price change in PRPH stock was $0.
-
PRPH's industry and sector of operation?
-
The OTC listed PRPH is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of PRPH?
-
Kevin Quinn | Chief Product Officer of Nebula Genomics
Ted William Karkus | Chairman & Chief Executive Officer
Jason Karkus | President of Nebula Genomics
|
| -
How many employees does PRPH have?
-
Number of PRPH employees currently stands at 19. PRPH operates from 626 RXR Plaz, Uniondale, NY 11556, US.
-
Link for PRPH official website?
-
Official Website of PRPH is: https://www.prophaselabs.com
-
How do I contact PRPH?
-
PRPH could be contacted at phone #215 345 0919 and can also be accessed through its website. PRPH operates from 626 RXR Plaz, Uniondale, NY 11556, US.
-
How many shares of PRPH are traded daily?
-
The average number of PRPH shares traded daily for last 3 months was 89.22K.
-
What is the market cap of PRPH currently?
-
The market value of PRPH currently stands at $700.81K with its latest stock price at $0.05